FDA Drug Safety Bulletin Being Considered To “Streamline” Communication
This article was originally published in The Tan Sheet
Executive Summary
Implementation of an FDA standard drug safety bulletin will be one area of focus for the agency's new Associate Director for Safety Policy & Communication Paul Seligman
You may also be interested in...
“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?
FDA is considering proactive communication of early adverse event reports from its MedWatch monitoring system as the agency reassesses its proposed Drug Watch website for emerging safety information
CDER reorganization
Center for Drug Evaluation & Research Director Stephen Galson announces he will appoint a new associate center director "to focus on broad drug safety policy and safety communication" as part of the planned reorganization of the center in a staff memo Nov. 4. The memo provides an update to the proposed CDER reorganization that Galson announced Oct. 19 in conjunction with the appointment of a new Office of Drug Safety head. "Consolidating certain drug safety-related activities to report to this new associate center director" was also suggested by Galson in the update. In addition to drug safety goals, Galson hopes CDER will embrace the Critical Path Initiative and "improve regulatory and drug development science." His suggestions include creating a new office that will report to the center director and "provide a locus in the center to catalyze Critical Path activities." In the memo, Galson announces the appointment of Paul Seligman, MD, to associate center director...
FDA Drug Watch System May "Confuse" Consumers In Proposed Form - CHPA
FDA should include drug safety information on its new Drug Watch system only after a review has "fully determined the significance of the information, causal or otherwise," according to the Consumer Healthcare Products Association